Drug General Information |
Drug ID |
D0F3MJ
|
Former ID |
DNC002574
|
Drug Name |
N-(3-(Aminomethyl)Benzyl)Acetamidine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C10H15N3
|
Canonical SMILES |
CC(=NCC1=CC(=CC=C1)CN)N
|
InChI |
1S/C10H15N3/c1-8(12)13-7-10-4-2-3-9(5-10)6-11/h2-5H,6-7,11H2,1H3,(H2,12,13)
|
InChIKey |
RODUKNYOEVZQPR-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
831299, 831308, 6901912, 7885015, 11111967, 11114075, 11120307, 11120795, 11121283, 11121656, 11122136, 11362725, 11365287, 11367849, 11370721, 11370722, 11373450, 11376011, 14748283, 24439771, 26752186, 26752187, 46507793, 47440020, 47662059, 47736240, 47959515, 48334249, 50074804, 50104843, 50104844, 53789084, 57320902, 78999485, 92310007, 99300919, 99302439, 103327181, 103838041, 103960539, 104097157, 104297722, 117516607, 124750361, 124881820, 124881821, 124881822, 124881823, 124881824, 125334777
|
Target and Pathway |
Target(s) |
Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[1]
|
Nitric oxide synthase, inducible |
Target Info |
Inhibitor |
[1]
|
Nitric-oxide synthase, brain |
Target Info |
Inhibitor |
[1]
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cycle
|
KEGG Pathway
|
Arginine and proline metabolism
|
Metabolic pathways
|
Calcium signaling pathway
|
cGMP-PKG signaling pathway
|
HIF-1 signaling pathway
|
Sphingolipid signaling pathway
|
PI3K-Akt signaling pathway
|
VEGF signaling pathway
|
Platelet activation
|
Estrogen signaling pathway
|
Oxytocin signaling pathwayhsa00220:Arginine biosynthesis
|
Peroxisome
|
Salmonella infection
|
Pertussis
|
Leishmaniasis
|
Chagas disease (American trypanosomiasis)
|
Toxoplasmosis
|
Amoebiasis
|
Tuberculosis
|
Pathways in cancer
|
Small cell lung cancerhsa00330:Arginine and proline metabolism
|
Phagosome
|
Circadian entrainment
|
Long-term depression
|
Salivary secretion
|
Alzheimer's disease
|
Amyotrophic lateral sclerosis (ALS)
|
NetPath Pathway
|
Wnt Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
IL2 Signaling PathwayNetPath_4:EGFR1 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
Endothelin signaling pathway
|
Interleukin signaling pathway
|
PI3 kinase pathway
|
VEGF signaling pathwayP06959:CCKR signaling map ST
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
Angiopoietin receptor Tie2-mediated signaling
|
Thromboxane A2 receptor signaling
|
SHP2 signaling
|
VEGFR1 specific signals
|
Signaling events mediated by VEGFR1 and VEGFR2
|
PAR1-mediated thrombin signaling eventsil12_2pathway:IL12-mediated signaling events
|
Alpha9 beta1 integrin signaling events
|
ATF-2 transcription factor network
|
IL23-mediated signaling events
|
Signaling mediated by p38-alpha and p38-beta
|
HIF-1-alpha transcription factor network
|
PathWhiz Pathway
|
Arginine and Proline Metabolism
|
Reactome
|
ROS production in response to bacteria
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
eNOS activation
|
Nitric oxide stimulates guanylate cyclase
|
VEGFR2 mediated vascular permeabilityR-HSA-1222556:ROS production in response to bacteria
|
Nitric oxide stimulates guanylate cyclaseR-HSA-1222556:ROS production in response to bacteria
|
WikiPathways
|
ACE Inhibitor Pathway
|
EGF/EGFR Signaling Pathway
|
Myometrial Relaxation and Contraction Pathways
|
JAK/STAT
|
Corticotropin-releasing hormone
|
AGE/RAGE pathway
|
Endothelin Pathways
|
Leptin signaling pathway
|
Effects of Nitric Oxide
|
Metabolism of nitric oxide
|
AngiogenesisWP619:Type II interferon signaling (IFNG)
|
Spinal Cord Injury
|
Effects of Nitric OxideWP727:Monoamine Transport
|
Amyotrophic lateral sclerosis (ALS)
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
Alzheimers Disease
|
Serotonin Transporter Activity
|
References |
REF 1 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. |